Cybin Inc

Research Cybin Inc (HELP) on Bullrun: market cap USD 343.27M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerHELP
• ExchangeNYSE MKT
• CountryCanada
• SectorHealthcare
• IndustryBiotechnology
• CurrencyUSD
• Market capUSD 343.27M
• Financial periodQ4 2025
• Net income-USD 42.67M
• Free cash flow-USD 32.33M

Valuation Snapshot

latest market cap is USD 343.27M.

About Cybin Inc

Cybin Inc., doing business as Helus Pharma, a clinical-stage neuropsychiatry company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions. It develops CYB003, a deuterated psilocybin analog, which is in phase 3 clinical trial to treat major depressive disorder (MDD); and CYB004, a deuterated N, N-dimethyltryptamine (DMT), which is in phase 2 clinical trial for treating generalized anxiety disorders.

Frequently asked questions

What is Cybin Inc's market cap?

Cybin Inc's market capitalization is USD 343.27M.

What does Cybin Inc do?

Cybin Inc., doing business as Helus Pharma, a clinical-stage neuropsychiatry company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions.